How Pfizer’s CEO wielded moral clarity to help his team do the impossible

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Pfizer (PFE) closes 2025 on solid note, returns $9.8B to shareholders

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks ...

Pfizer’s CEO on leading after a moonshot—and making deals with Trump

Also: All the news and watercooler chat from Fortune.

Pfizer CEO discusses the company's GLP-1 weigh-loss drug pipeline

Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...

Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...

Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.

Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...
Insider Monkey

Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...